Government-Owned Invention; Availability for Licensing, 81149 [2016-27676]

Download as PDF Federal Register / Vol. 81, No. 222 / Thursday, November 17, 2016 / Notices or requirements that members of the public submit reports, keep records, or provide information to a third party. Section 3506(c)(2)(A) of the PRA requires federal agencies to publish a 60-day notice in the Federal Register concerning each proposed collection of information, including each proposed extension or reinstatement of an existing collection of information, before submitting the collection to OMB for approval. To comply with this requirement, CMS is publishing this notice. Information Collection 1. Type of Information Collection Request: Extension of a currently approved collection; Title of Information Collection: Medicare/ Medicaid Demonstration/Model Application; Use: The application is used for solicitation of proposals that are either congressionally mandated or Administration high priority demonstration initiatives which would be used to strengthen and modernize the Medicare and/or Medicaid programs. The standardized proposal format is not controversial and will reduce burden on applicants and reviewers. Responses are strictly voluntary. The standard format will enable CMS to select proposals that meet CMS objectives and show the best potential for success. Form Number: CMS–10069 (OMB control number: 0938–0880); Frequency: Once; Affected Public: Private sector—Business or other for-profits and Not-for-profit institutions; Number of Respondents: 75; Total Annual Responses: 75; Total Annual Hours: 6,000. (For policy questions regarding this collection contact John Amoh at 410–786–4910). Dated: November 10, 2016. William N. Parham, III, Director, Paperwork Reduction Staff, Office of Strategic Operations and Regulatory Affairs. [FR Doc. 2016–27550 Filed 11–16–16; 8:45 am] BILLING CODE 4120–01–P DEPARTMENT OF HEALTH AND HUMAN SERVICES asabaliauskas on DSK3SPTVN1PROD with NOTICES National Institutes of Health Government-Owned Invention; Availability for Licensing AGENCY: National Institutes of Health, HHS. ACTION: Notice. The invention listed below is owned by an agency of the U.S. Government and is available for licensing in the U.S. to achieve SUMMARY: VerDate Sep<11>2014 21:24 Nov 16, 2016 Jkt 241001 expeditious commercialization of results of federally-funded research and development. Foreign patent applications are filed on selected inventions to extend market coverage for companies and may also be available for licensing. FOR FURTHER INFORMATION CONTACT: Licensing information may be obtained by communicating with the indicated licensing contact at the Technology Transfer and Intellectual Property Office, National Institute of Allergy and Infectious Diseases, 5601 Fishers Lane, Rockville, MD 20852; tel. 301–496– 2644. A signed Confidential Disclosure Agreement will be required to receive copies of unpublished scientific data. SUPPLEMENTARY INFORMATION: Technology description follows. Polyvalent Influenza Virus-Like Particles (VLPs) and Use as Vaccines Description of Technology: This viruslike particle (VLP) vaccine technology for influenza viruses, based on a mixture of VLPs expressing the hemagglutinin protein or the neuraminidase protein from influenza virus strains belonging to different virus subtypes, has demonstrated broad protection against lethal challenge in mice with various influenza virus strains and virus subtypes. Results from ferret and mouse studies demonstrate broad heterosubtypic protection against various influenza virus subtypes further supporting and strengthening the proposed application of this technology as a universal influenza virus vaccine. This technology is available for licensing for commercial development in accordance with 35 U.S.C. 209 and 37 CFR part 404, as well as for further development and evaluation under a research collaboration. Potential Commercial Applications: • Vaccines Competitive Advantages: • Broad/universal protection against influenza viruses • does not require reformulating vaccine each year as is currently necessary with vaccines available on the market • can potentially provide protection against novel influenza viruses that may arise in the future, including potentially pandemic influenza viruses Inventors: Dr. Jeffery Taubenberger of NIAID. Publications: Schwartzman, et al. An Intranasal Virus-Like Particle Vaccine Broadly Protects Mice from Multiple Subtypes of Influenza A Virus. 2015. MBio. 6(4): e01044–15. Intellectual Property: HHS Reference No. E–195–2014, U.S. Provisional PO 00000 Frm 00097 Fmt 4703 Sfmt 4703 81149 Application No. 62/014,814; PCT/ US2015/029843. Licensing Contact: Dr. Jenish Patel, (240) 669–2894, jenish.patel@nih.gov. Collaborative Research Opportunity: The National Institute of Allergy and Infectious Diseases is seeking statements of capability or interest from parties interested in collaborative research to further develop, evaluate or commercialize this invention, especially for GMP manufacture and clinical evaluation. For collaboration opportunities, please contact Dr. Jenish Patel, (240) 669–2894, jenish.patel@ nih.gov. Dated: November 14, 2016. Suzanne Frisbie, Deputy Director, Technology Transfer and Intellectual Property Office, National Institute of Allergy and Infectious Diseases. [FR Doc. 2016–27676 Filed 11–16–16; 8:45 am] BILLING CODE 4140–01–P DEPARTMENT OF HEALTH AND HUMAN SERVICES National Institutes of Health National Institute of Allergy and Infectious Diseases; Notice of Closed Meetings Pursuant to section 10(d) of the Federal Advisory Committee Act, as amended (5 U.S.C. App.), notice is hereby given of the following meetings. The meetings will be closed to the public in accordance with the provisions set forth in sections 552b(c)(4) and 552b(c)(6), Title 5 U.S.C., as amended. The grant applications and the discussions could disclose confidential trade secrets or commercial property such as patentable material, and personal information concerning individuals associated with the grant applications, the disclosure of which would constitute a clearly unwarranted invasion of personal privacy. Name of Committee: National Institute of Allergy and Infectious Diseases Special Emphasis Panel; ‘‘Advancing HIV Therapeutic Vaccine Science (U01)’’. Date: December 12, 2016. Time: 10:00 a.m. to 4:00 p.m. Agenda: To review and evaluate grant applications. Place: National Institutes of Health, 5601 Fishers Lane, Rockville, MD 20892 (Telephone Conference Call). Contact Person: Jay R. Radke, Ph.D., AIDS Review Branch, Scientific Review Program, Division of Extramural Activities, Room #3G11B, National Institutes of Health, NIAID, 5601 Fishers Lane MSC–9823, Bethesda, MD 20892–9823, (240) 669–5046, jay.radke@ nih.gov. Name of Committee: National Institute of Allergy and Infectious Diseases Special E:\FR\FM\17NON1.SGM 17NON1

Agencies

[Federal Register Volume 81, Number 222 (Thursday, November 17, 2016)]
[Notices]
[Page 81149]
From the Federal Register Online via the Government Publishing Office [www.gpo.gov]
[FR Doc No: 2016-27676]


-----------------------------------------------------------------------

DEPARTMENT OF HEALTH AND HUMAN SERVICES

National Institutes of Health


Government-Owned Invention; Availability for Licensing

AGENCY: National Institutes of Health, HHS.

ACTION: Notice.

-----------------------------------------------------------------------

SUMMARY: The invention listed below is owned by an agency of the U.S. 
Government and is available for licensing in the U.S. to achieve 
expeditious commercialization of results of federally-funded research 
and development. Foreign patent applications are filed on selected 
inventions to extend market coverage for companies and may also be 
available for licensing.

FOR FURTHER INFORMATION CONTACT: Licensing information may be obtained 
by communicating with the indicated licensing contact at the Technology 
Transfer and Intellectual Property Office, National Institute of 
Allergy and Infectious Diseases, 5601 Fishers Lane, Rockville, MD 
20852; tel. 301-496-2644. A signed Confidential Disclosure Agreement 
will be required to receive copies of unpublished scientific data.

SUPPLEMENTARY INFORMATION: Technology description follows.

Polyvalent Influenza Virus-Like Particles (VLPs) and Use as Vaccines

    Description of Technology: This virus-like particle (VLP) vaccine 
technology for influenza viruses, based on a mixture of VLPs expressing 
the hemagglutinin protein or the neuraminidase protein from influenza 
virus strains belonging to different virus subtypes, has demonstrated 
broad protection against lethal challenge in mice with various 
influenza virus strains and virus subtypes. Results from ferret and 
mouse studies demonstrate broad heterosubtypic protection against 
various influenza virus subtypes further supporting and strengthening 
the proposed application of this technology as a universal influenza 
virus vaccine.
    This technology is available for licensing for commercial 
development in accordance with 35 U.S.C. 209 and 37 CFR part 404, as 
well as for further development and evaluation under a research 
collaboration.
    Potential Commercial Applications:
     Vaccines
    Competitive Advantages:
     Broad/universal protection against influenza viruses
     does not require reformulating vaccine each year as is 
currently necessary with vaccines available on the market
     can potentially provide protection against novel influenza 
viruses that may arise in the future, including potentially pandemic 
influenza viruses
    Inventors: Dr. Jeffery Taubenberger of NIAID.
    Publications: Schwartzman, et al. An Intranasal Virus-Like Particle 
Vaccine Broadly Protects Mice from Multiple Subtypes of Influenza A 
Virus. 2015. MBio. 6(4): e01044-15.
    Intellectual Property: HHS Reference No. E-195-2014, U.S. 
Provisional Application No. 62/014,814; PCT/US2015/029843.
    Licensing Contact: Dr. Jenish Patel, (240) 669-2894, 
jenish.patel@nih.gov.
    Collaborative Research Opportunity: The National Institute of 
Allergy and Infectious Diseases is seeking statements of capability or 
interest from parties interested in collaborative research to further 
develop, evaluate or commercialize this invention, especially for GMP 
manufacture and clinical evaluation. For collaboration opportunities, 
please contact Dr. Jenish Patel, (240) 669-2894, jenish.patel@nih.gov.

    Dated: November 14, 2016.
Suzanne Frisbie,
Deputy Director, Technology Transfer and Intellectual Property Office, 
National Institute of Allergy and Infectious Diseases.
[FR Doc. 2016-27676 Filed 11-16-16; 8:45 am]
 BILLING CODE 4140-01-P